Innovative Drug Development for Geriatric Overactive Bladder: Formulation and Assessment of Orally Disintegrating Tablets

OAB syndrome, or overactive bladder, is a long-term medical issue that significantly affects a large portion of the population's quality of life in the geriatric populace. Mirabegron is a BCS Class III drug with poor bioavailability and lack of solubility to show quick response. Mirabegron exerts its effect by relaxing the detrusor muscle through selective activation of β3-adrenergic receptors, resulting in increased bladder capacity and decreased urgency. The work aimed to develop an oral disintegrating tablet containing mirabegron thereby improving the solubility and overcoming poor bioavailability. An oral disintegrating tablet of mirabegron was prepared by lyophilization technique. Menthol is used as a pore-forming agent. Sucrose is applied as an improvement in flavoring agent. The orally disintegrating tablet Weight variation, wetting time, friability, disintegration time, and content homogeneity were assessed along with ex vivo permeation and in vitro studies. The optimized formulation F7 showed uniform drug content, disintegrated, and wetted in less than one minute. The studies on friability showed that the tablets had good mechanical strength. Ex vivo permeation studies proved good solubility and better permeation because of the porous character of the tablets developed by the lyophilization method. In light of the results, it may be said that the developed oral disintegrated tablet equipped with uniform-size and porous nature enhanced dissolution which led to enhanced oral bioavailability of mirabegron.